Mine & Arao Wealth Creation & Management LLC. Sells 200 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mine & Arao Wealth Creation & Management LLC. decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 414 shares of the medical research company’s stock after selling 200 shares during the period. Mine & Arao Wealth Creation & Management LLC.’s holdings in Thermo Fisher Scientific were worth $216,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in TMO. Quarry LP lifted its position in shares of Thermo Fisher Scientific by 86.2% during the 2nd quarter. Quarry LP now owns 121 shares of the medical research company’s stock worth $67,000 after buying an additional 56 shares during the period. Brown Financial Advisors bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $671,000. Heritage Wealth Management Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth about $334,000. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Thermo Fisher Scientific by 0.4% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 68,321 shares of the medical research company’s stock valued at $37,782,000 after purchasing an additional 264 shares during the last quarter. Finally, Centaurus Financial Inc. grew its stake in Thermo Fisher Scientific by 3.3% during the second quarter. Centaurus Financial Inc. now owns 6,283 shares of the medical research company’s stock worth $3,475,000 after buying an additional 201 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

TMO opened at $607.06 on Friday. The company has a fifty day simple moving average of $537.83 and a 200 day simple moving average of $570.33. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a market cap of $232.20 billion, a P/E ratio of 38.06, a P/E/G ratio of 3.89 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 29,000 shares of company stock valued at $15,859,540. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TMO. Royal Bank of Canada reduced their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Bank of America lowered their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.